甘草酸作用机制 - Medchemexpress - MCE中国

1、Product Data SheetGlycyrrhizic acidCat. No.: HY-N0184CAS No.: 1405-86-3分式: CHO分量: 822.93作靶点: Virus Protease作通路: Anti-infection储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 100 mg/mL (121.52 mM)H2O : 0.1 mg/mL (insoluble)* means soluble, but saturation unknown

2、.SolventMass1 mg 5 mg 10 mgConcentration制备储备液1 mM 1.2152 mL 6.0759 mL 12.1517 mL5 mM 0.2430 mL 1.2152 mL 2.4303 mL10 mM 0.1215 mL 0.6076 mL 1.2152 mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 储存时，请在 6 个内使，-20C 储存时，请在 1 个内使。体内实验请根据您的实验动物和给药式选择适

3、当的溶解案。以下溶解案都请先按照 In Vitro 式配制澄清的储备液，再依次添加助溶剂：为保证实验结果的可靠性，澄 的储备液可以根据储存条件，适当保存；体内实验的作液，建议您现现配，当天使； 以下溶剂前显的百分 指该溶剂在您配制终溶液中的体积占；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的式助溶1. 请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 10 mg/mL (12.15 mM); Clear solution此案可获得 10 mg/mL (12.15 mM，饱和度未知) 的澄清溶液。以 1

4、 mL 作液为例，取 100 L 100.0 mg/mL 的澄 DMSO 储备液加到 400 L PEG300 中，混合均匀；向上述体系中加50 L Tween-80，混合均匀；然后继续加 450 L 理盐定容 1 mL。2. 请依序添加每种溶剂： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 10 mg/mL (12.15 mM); Clear solutionPage 1 of 2 www.MedChemE此案可获得 10 mg/mL (12.15 mM，饱和度未知) 的澄清溶液。以 1 mL 作液为例，取 100 L 100.0 mg/mL

5、 的澄 DMSO 储备液加到 900 L 20% 的 SBE-CD 理盐溶液中，混合均匀。3. 请依序添加每种溶剂： 10% DMSO 90% corn oilSolubility: 10 mg/mL (12.15 mM); Clear solution此案可获得 10 mg/mL (12.15 mM，饱和度未知) 的澄 溶液，此案不适于实验周 期在半个以上的实验。以 1 mL 作液为例，取 100 L 100.0 mg/mL 的澄 DMSO 储备液加到 900 L 油中，混合均匀。4. 请依序添加每种溶剂： 10% DMSO 90% salineSolubility: 10 mg/mL (1

6、2.15 mM); Clear solution; Need ultrasonic and warmingBIOLOGICAL ACTIVITY物活性 Glycyrrhizic acid草的活性成分三萜皂苷，为 HMGB1 的拮抗剂，具有抗肿瘤、抗糖尿病等功效。体外研究 Glycyrrhizic acid shows a series of anti-cancer-related pharmacological activities, such as broad-spectrum anti-cancerability, resistance to the tissue toxicity cau

7、sed by chemotherapy and radiation, drug absorption enhancing effects andanti-multidrug resistance (MDR) mechanisms, as a carrier material in drug delivery systems1. In intestinal NCI-H716cells that secretes GLP-1, Glycyrrhizic acid promotes GLP-1 secretion with a marked elevation of calcium levels.G

8、lycyrrhizic acid can enhance GLP-1 secretion through TGR5 activation2.体内研究 In type 1-like diabetic rats induced by streptozotocin (STZ-treated rats), Glycyrrhizic acid increases the level of plasmaGLP-1, which is blocked by triamterene at a dose sufficient to inhibit Takeda G-protein-coupled recepto

9、r 5 (TGR5)1.Glycyrrhizic acid (Glycyrrhizic acid; 50 mg/kg, i.p.) significantly decreases the levels of TgAb, HMGB1, TNF-, IL-6, IL-1in mice3.PROTOCOLAnimal Mice3Administration 3 NOD.H-2h4 mice are fed in the animal house until 4 weeks of age. A total of 24 male mice are then randomlyseparated into

10、three different groups (n=8 per group). Mice in the control group are given sterile water withoutsupplement. Mice in the iodine supplement (NaI) group are given 0.005% NaI in the drinking water. Mice in theNaI+Glycyrrhizic acid group are treated with 50 mg/kg Glycyrrhizic acid once daily for 4 weeks

11、, administered viaintraperitoneal injection after 8 weeks of iodine supplementation. Thyroid tissues are removed surgically underanesthesia, washed with cold saline, blotted on filter paper and weighed using an electronic balance. The thyroidgland tissues are then stored at -80C until use3.MCE has n

12、ot independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Aging (Albany NY). 2019 Jul 7;11(13):4323-4337. Cell Prolif. 2020 May 17;e12829. ACS Chem Neurosci. 2020 Feb.See more customer validations on HYPERLINK www.MedChemE www.MedChemEPage 2 of 3 www.MedChemER

13、EFERENCES1. Su X, et al. Glycyrrhizic acid: A promising carrier material for anticancer therapy. Biomed Pharmacother. 2017 Sep 5;95:670-6782. Wang LY, et al. Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats. Biomed Pharmacother. 2017Sep 4;95:599-604.3. Li C, et al. Glycyrrhizin, a Direct HMGB1 Antagonist, Ameliorates Inflammatory Infiltration in a Model of Autoimmune Thyroiditis via Inhibition of TLR2-HMGB1 Signaling. Thyroid. 2017 May;27(5):722-731.McePdfHeightCaut